Cooper Companies, Inc. (NYSE: COO) Securities Fraud Investigation

Gilman Law LLP’s Naples Florida Office Announces Securities Fraud Lawsuit Against The Cooper Companies, Inc. 

Gilman Law LLP, a leading national securities law firm located in Naples, Florida, is actively investigating shareholder allegations that The Cooper Companies, Inc. (“Cooper”) and certain of its officers and directors made materially false and misleading statements or failed to disclose material information related to the company’s business and operations in violation of the Securities Exchange Act of 1940.

For over 40 years, the Naples, Florida lawyers at Gilman Law have been involved in all major aspects of securities fraud litigation. The Naples Florida securities lawyers focus on cases involving stock manipulation, securities fraud, and shareholder rights violations.

If you purchased or otherwise acquired shares of Cooper (NYSE: COO) between March 4, 2011 and November 15, 2011, (“Class Period”), and either lost money on the transaction or still hold the shares, you may contact the Naples, Florida Securities Lawyers of Gilman Law LLP by no later than January 27, 2012 (“Class Period”) to exercise your rights against Cooper.

Based in Pleasanton, California, Cooper, through its wholly-owned subsidiary CooperVision, develops, manufactures and globally markets contact lenses.  A shareholder class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of purchasers of the common stock of Cooper between March 4, 2011 and November 15, 2011.

If you are a member of the Class, you may join this class action at www.investment-losses.com. The firm’s Naples office is offering free legal consultations to investors throughout Florida, including Naples, Orlando, Miami, Jacksonville, and Tampa.

Cooper Allegedly Issued False and Misleading Information that Artificially Inflated Stock Prices

The complaint alleges that Cooper violated the Securities Exchange Act by failing to disclose the following facts: (1) Cooper failed to disclose that CooperVisions’s new Puerto Rico and UK manufacturing facilities were experiencing serious manufacturing process defects and quality control problems, resulting in dangerously high levels of silicone oil residue being left on the contact lenses; (2) Cooper contact lens users were experiencing high incidents of severe eye pain, torn corneas, and requiring extensive medical treatment; (3) CooperVision’s sales of contact lenses would be adversely impacted once physicians learned of the quality control and product safety problems as they would stop prescribing Cooper lenses; and (4) Cooper had intentionally downplayed the extent of the Company’s quality control problems and the breadth of products involved in the August 2011 recall announcement.  As a result, it was not possible for the Company to meet the fiscal 2011 and 4Q 2011 financial guidance during the Class Period.

If you purchased shares of Cooper during the Class Period and would like to consider serving as lead plaintiff or have any questions about the lawsuit, please contact Kenneth G. Gilman, Esq. of Naples, Florida Gilman Law LLP at (888) 252-0048 or visit complete the form above.  Lead Plaintiff motion papers must be filed with the Court no later than January 27, 2012.  A Lead Plaintiff is a court-appointed representative for absent class members. You do not need to seek appointment as Lead Plaintiff to share in any class recovery in this action.  If you are a class member and there is a recovery for the class, you can share in that recovery as an absent class member. You may retain counsel of your choice to represent you in this action.

Gilman Law LLP’s Naples Florida office has extensive experience representing both individual and institutional investors in securities class action suits.  The Naples, Florida Securities Lawyers at Gilman Law have recovered over a billion dollars for its clients and can help you recover any losses that you have incurred as a result of Cooper’s fraudulent practices.  For a free evaluation of your case or to obtain additional information, please complete the form above or CALL TOLL FREE (888) 252-0048.